Suppr超能文献

接受抗血管内皮生长因子药物玻璃体腔内注射治疗的糖尿病黄斑水肿患者的视网膜层变化:一项频域光相干断层扫描研究的长期结果。

Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.

机构信息

2nd Department of Ophthalmology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece,

2nd Department of Ophthalmology, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Ophthalmic Res. 2021;64(2):230-236. doi: 10.1159/000509552. Epub 2020 Jun 19.

Abstract

PURPOSE

The purpose of this study was to investigate retinal layers' changes in patients with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor (anti-VEGF) agents and to evaluate if these changes may affect treatment response.

METHODS

Participants in this prospective study were 110 treatment-naïve patients with center involved DME, who were treated with anti-VEGF agents and followed up for at least 12 months. A qualitative and quantitative analysis of retinal layers that can affect visual acuity was performed. Patients with persistent DME were defined, and factors which could affect this outcome were determined.

RESULTS

Visual acuity was significantly improved, while there was also a statistically significant reduction in central retinal thickness and in all separate retinal layers' thickness at month 12 compared to baseline (p < 0.001). Visual acuity was associated with central retinal thickness and outer retinal layers' thickness;51.8% of the patients presented with persistent DME at month 12, which was found to be significantly associated with baseline visual acuity and HbA1C levels.

CONCLUSIONS

Anti-VEGF treatment is effective in reducing retinal thickness as a whole and in all separate retinal layers at 12-month follow-up in patients with DME. Changes in central retinal thickness and in outer retinal layers were found to affect visual acuity. HbA1c was the most significant factor to determine persistence of DME at month 12.

摘要

目的

本研究旨在探讨接受抗血管内皮生长因子(anti-VEGF)药物治疗的糖尿病性黄斑水肿(DME)患者的视网膜层变化,并评估这些变化是否会影响治疗反应。

方法

本前瞻性研究纳入了 110 名初次接受治疗的中心性 DME 患者,他们接受了抗 VEGF 药物治疗,并随访至少 12 个月。对可能影响视力的视网膜层进行定性和定量分析。定义了持续性 DME 的患者,并确定了可能影响这一结果的因素。

结果

与基线相比,视力在第 12 个月时显著提高,而中央视网膜厚度和所有单独视网膜层的厚度也有统计学意义的降低(p<0.001)。视力与中央视网膜厚度和外视网膜层厚度相关;51.8%的患者在第 12 个月时出现持续性 DME,这与基线视力和 HbA1C 水平显著相关。

结论

抗 VEGF 治疗在 12 个月随访时可有效降低 DME 患者的整体视网膜厚度和所有单独视网膜层的厚度。中央视网膜厚度和外视网膜层的变化会影响视力。HbA1c 是第 12 个月时决定 DME 持续存在的最重要因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验